137 related articles for article (PubMed ID: 16734360)
1. [Three-year experience with the use of cefoperazone/sulbactam (sulperazone) in the treatment of hospital-acquired infections in an oncologic hospital].
Antibiot Khimioter; 2006; 51(1):14-7. PubMed ID: 16734360
[TBL] [Abstract][Full Text] [Related]
2. [Clinical experience with the treatment of severe nosocomial infections by inhibitor-protected 3rd generation cephalosporin cefoperazone/sulbactam].
Beloborodova NV; Kuznetsova ST; Popov DA; Bachinskaia EN; Vostrikov TIu
Antibiot Khimioter; 2005; 50(4):33-40. PubMed ID: 16392338
[TBL] [Abstract][Full Text] [Related]
3. [A trial of using sulperazone (cefoperazone/sulbactam) in the combined treatment of patients with a burn infection].
Iakovlev VP; Krutikov MG; Alekseev AA; Grishina IA; Izotova GN; Kashin IuD
Antibiot Khimioter; 1995 May; 40(5):38-41. PubMed ID: 8534180
[TBL] [Abstract][Full Text] [Related]
4. [Sulperazone in the treatment of severe infections in patients with cancer].
Mitrokhin SD
Antibiot Khimioter; 2003; 48(3):26-9. PubMed ID: 12914118
[TBL] [Abstract][Full Text] [Related]
5. [Changes of antimicrobial resistance among nonfermenting gram-negative bacilli isolated from intensive care units from 1994 to 2001 in China].
Wang H; Chen MJ;
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):385-90. PubMed ID: 12820914
[TBL] [Abstract][Full Text] [Related]
6. Sulbactam-containing beta-lactamase inhibitor combinations.
Akova M
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():185-8. PubMed ID: 18154545
[TBL] [Abstract][Full Text] [Related]
7. [Use of a combination of cefoperazone with sulbactam for treatment of patients with wound infections].
Iakovlev VP; Blatun LA; Puchkova LS; Svetukhin AM
Antibiot Khimioter; 1994 Dec; 39(12):31-4. PubMed ID: 7733785
[TBL] [Abstract][Full Text] [Related]
8. Use of cefoperazone/sulbactam in neonates.
Ovali F; Gursoy T; Sari I; Divrikli D; Aktas A
Pediatr Int; 2012 Feb; 54(1):60-3. PubMed ID: 21883691
[TBL] [Abstract][Full Text] [Related]
9. Cefoperazone-sulbactam for treatment of intra-abdominal infections: results from a randomized, parallel group study in India.
Chandra A; Dhar P; Dharap S; Goel A; Gupta R; Hardikar JV; Kapoor VK; Mathur AK; Modi P; Narwaria M; Ramesh MK; Ramesh H; Sastry RA; Shah S; Virk S; Sudheer OV; Sreevathsa MR; Varshney S; Kochhar P; Somasundaram S; Desai C; Schou M
Surg Infect (Larchmt); 2008 Jun; 9(3):367-76. PubMed ID: 18570578
[TBL] [Abstract][Full Text] [Related]
10. A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of cefoperazone/sulbactam.
Xia J; Zhang D; Xu Y; Gong M; Zhou Y; Fang X
Int J Infect Dis; 2014 Jun; 23():90-3. PubMed ID: 24726664
[TBL] [Abstract][Full Text] [Related]
11. Comparative in-vitro activity of cefoperazone-tazobactam and cefoperazone-sulbactam combinations against ESBL pathogens in respiratory and urinary infections.
Patankar M; Sukumaran S; Chhibba A; Nayak U; Sequeira L
J Assoc Physicians India; 2012 Nov; 60():22-4. PubMed ID: 23767198
[TBL] [Abstract][Full Text] [Related]
12. [Use of sulperazone in acute surgical conditions].
Grosmanová T; Klementa I; Král V; Kolár M
Bratisl Lek Listy; 1999 Dec; 100(12):709-11. PubMed ID: 10847756
[TBL] [Abstract][Full Text] [Related]
13. In-vitro activity of cefoperazone-sulbactam combination against cefoperazone resistant clinical isolates in a Malaysian general hospital.
Lim VK; Cheong YM
Malays J Pathol; 1995 Dec; 17(2):73-6. PubMed ID: 8935129
[TBL] [Abstract][Full Text] [Related]
14. [Activity of cefoperazone and cefoperazone-sulbactam against gram-positive and gram-negative bacteria].
Baykal M; Hasçelik G
Mikrobiyol Bul; 1990 Oct; 24(4):383-5. PubMed ID: 2287298
[TBL] [Abstract][Full Text] [Related]
15. Antibacterial activity of cefoperazone and cefoperazone plus sulbactam in a neutropenic site model.
Fasching CE; Moody JA; Sinn LM; Tenquist J; Gerding DN; Peterson LR
Diagn Microbiol Infect Dis; 1991; 14(2):147-55. PubMed ID: 1873973
[TBL] [Abstract][Full Text] [Related]
16. [Sulperazone--a combined form of cefoperazone with sulbactam].
Iakovlev VP
Antibiot Khimioter; 1995 Feb; 40(2):55-70. PubMed ID: 7605145
[No Abstract] [Full Text] [Related]
17. [Cefoperazone-sulbactam plus minocycline in the treatment of extensively drug resistant Acinetobacter infections].
Shi Y; Xu YC; Liu Y; Du W; Rui X; Wang Y
Zhonghua Yi Xue Za Zhi; 2012 Oct; 92(40):2847-50. PubMed ID: 23290215
[TBL] [Abstract][Full Text] [Related]
18. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
Nomura S; Hanaki H; Nagayama A
J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
Mohanty S; Singhal R; Sood S; Dhawan B; Das BK; Kapil A
Indian J Med Res; 2005 Nov; 122(5):425-8. PubMed ID: 16456257
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of drug resistance of Pseudomonas aeruginosa and use of antibiotics in burn wards during 6 years].
Dou Y; Zhang Q
Zhonghua Shao Shang Za Zhi; 2014 Feb; 30(1):9-14. PubMed ID: 24684983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
